The treatment contains antibodies, which are usually produced naturally in response to a COVID infection or vaccination. They work by recog...

AZD7442 is dubbed as the first long acting antibody (LAAB) with Phase III data to demonstrate benefit.

The experimental monoclonal antibodies therapy, called AZD7442, reduced the risk of severe COVID-19 or death by half in non-hospitalised pa...

"An early intervention with our antibody can give a significant reduction in progression to severe disease, with continued protection for m...

The treatment, an antibody therapy called AZD7442, had reduced the risk of people developing any COVID-19 symptoms by 77% in a late-stage t...

Anglo-Swedish pharma company AstraZeneca has mobilised research efforts to advance the development of a novel coronavirus-neutralising long...

The drug, made from a combination of two antibodies, failed its main goal to treat Covid-19 symptoms in exposed patients, AstraZeneca said ...

The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the co...

The antibody therapy, which has yet to be approved by U.S. regulators, is designed to treat the disease rather than prevent it like the vac...

The drug known as AZD7442 has the potential to be given as a preventative option for people exposed to the coronavirus, and to treat and pr...